Products - Pipeline
Cao Pharmaceuticals has designed next generation CPT derivatives that demonstrate increased activity in vitro of ten fold and even 100 fold compared to currently approved chemotherapy drugs. They are developing an improved design of a currently approved CPT based drug which should increase the activity and reduce the toxicity. These products along with promising newly synthesized drugs will be developed in parallel to their lead drug CZ48.
The company's founder, Zhisong Cao, holds the patent rights for CZ48 which has demonstrated superior efficacy against a broad spectrum of cancers grown in nude mice. These cancers are listed in the table below. In sharp contrast to most chemotherapy drugs, this CPT based drug has shown almost no detectable toxicity in the nude mouse growing these human tumors.
Total inhibition seen of human tumors grown in nude mice by oral administration in 28 out of 29 patients diagnosed with 10 different tumor types (specified below). Note: Desmoplastic small round cell tumor (DSRCT) is an aggressive and rare cancer that primarily occurs as masses in the abdomen, although it may occur in other areas. It is considered an adolescent cancer, although occasionally occurring in adults. Because the number of new cases per year is relatively small, little research is done on this form of cancer. We are excited that this drug, along with several other CPT based drugs are effective against DSRCT. Cao Pharmaceuticals hopes to initiate Phase II trials to treat patients with DSRCT in 2019.